Biotech | January 29, 2022
Israel signs deal to purchase Novavax’ Covid-19 vaccine
It would be the first protein-based alternative available in Israel
It would be the first protein-based alternative available in Israel
Pfizer is evaluating the FDA’s comments and will work with the agency to determine an appropriate path forward
Previously, the use of the drug was limited to patients requiring hospitalization
First launches expected in H1 2022
They will commercialize molnupiravir in the international markets
This surpasses the number of approvals supported in 2020
Health experts of the country have pointed out that the benefits of the drug outweigh the potential risks it may have in the case of high-risk patients
Novavax' vaccine has received authorizations of the vaccine in over 170 countries
Earlier last week the U.S. FDA had also shortened the time to receive a Pfizer booster shot from six months to five months for everyone 12 and older
The drug is priced at Rs 2000 for a course of 40 tablets
Subscribe To Our Newsletter & Stay Updated
